BB Biotech

BB Biotech AG is a Swiss investment company focused exclusively on the biotechnology sector. Unlike a conventional pharmaceutical manufacturer, it does not primarily research, manufacture, or sell medicines under its own product brand. Its role is to allocate capital to publicly traded and, within limits, privately held biotechnology companies whose scientific programs and commercial prospects may create long-term value. The company is managed by Bellevue Asset Management AG, a Zurich-based investment manager belonging to Bellevue Group. BB Biotech was established as a Swiss Aktiengesellschaft in Schaffhausen on November 9, 1993. Its shares began trading on the SIX Swiss Exchange on December 27 of the same year. The company subsequently expanded its trading presence to Germany, where its shares were admitted to the Frankfurt market in 1997, and to Italy, where they traded from 2000 until September 2023. BB Biotech was included in the German TecDAX during two periods, first from 2003 to June 2012 and later from September 2012 to June 2015. These listings helped position it as a specialist listed vehicle for investors seeking exposure to biotechnology rather than as an operating drug company. The company is structured as a closed-end investment fund. Its investment mandate concentrates on biotechnology companies, particularly small- and medium-capitalization businesses headquartered in the United States and Western Europe. BB Biotech's target areas include oncology, neurological and metabolic disorders, cardiovascular disease, infectious disease, and autoimmune conditions. It also places particular emphasis on therapeutic platforms involving cell therapy, gene therapy, and RNA-based technologies. The portfolio approach favors companies with marketed products or drug candidates in relatively advanced stages of development, rather than relying solely on very early research projects. Investment decisions are made through a bottom-up process based on fundamental analysis and are benchmarked against the Nasdaq Biotechnology Index in Swiss francs. The portfolio generally contains approximately 35 holdings. A smaller group of roughly five to eight core positions normally represents the majority of portfolio value, while a broader set of smaller holdings provides exposure to additional development programs and commercial opportunities. The company may also invest a limited portion of its assets in unlisted biotechnology businesses. BB Biotech describes itself as a long-only investor: it buys and holds equity positions rather than using short selling as a central investment strategy. The investment-management, research, marketing, and administration functions are delegated to Bellevue Asset Management. BB Biotech holds its interests in portfolio companies indirectly through wholly owned Curaçao-based subsidiaries, including Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V. Its portfolio has included biotechnology companies such as Argenx, Ionis Pharmaceuticals, Neurocrine Biosciences, Intra-Cellular Therapies, Revolution Medicines, Vertex, Alnylam Pharmaceuticals, and Incyte, although holdings can change as the investment committee adjusts exposure. BB Biotech's positioning combines the accessibility of a listed security with specialist exposure to a sector characterized by scientific uncertainty, clinical risk, regulatory review, and potentially significant product-driven growth. Its identity is therefore that of a dedicated biotechnology investment company rather than a consumer-facing healthcare brand. Governance is provided by a board of directors, while Bellevue Asset Management supplies the specialist portfolio-management platform.

BB Biotech was created in Schaffhausen, Switzerland, on November 9, 1993, as an Aktiengesellschaft dedicated to investment in biotechnology companies. Its shares began trading on the SIX Swiss Exchange on December 27, 1993. From the outset, the company provided a listed route to specialist biotechnology exposure, distinguishing itself from operating pharmaceutical businesses because its principal activity was the ownership and management of equity investments. The company broadened its capital-market presence during the following decade. Its shares were admitted to the German Deutsche Börse in Frankfurt on December 10, 1997. In Italy, BB Biotech began trading on the Nuovo Mercato on October 19, 2000, later moving into the Star segment in September 2005. It was included in the TecDAX from 2003 until June 2012, returned to that index in September 2012, and remained there until June 2015. The Italian listing ended on September 4, 2023. BB Biotech developed into a major specialist investment company in biotechnology. Its investment universe has primarily covered the United States and Western Europe, with an emphasis on small- and medium-capitalization companies. The investment mandate spans therapeutic areas including cancer, neurological disease, metabolic disorders, cardiovascular disease, infectious disease, and autoimmune conditions. More recently, the approach has also highlighted cell, gene, and RNA-based therapeutic technologies. The company operates as a closed-end fund and follows a long-only investment model. It does not depend on short positions or other derivatives-based strategies to offset individual-company or market risk. Instead, its managers use fundamental, bottom-up analysis to select companies that have marketed products or drug candidates in advanced development. The portfolio is generally organized around a limited number of core holdings, supported by a larger group of smaller positions and, within a defined limit, investments in privately held biotechnology companies. Bellevue Asset Management AG, part of Bellevue Group and based in Zurich, is responsible for fundamental research, portfolio management, marketing, and administration. BB Biotech's investments are held indirectly through wholly owned Curaçao subsidiaries known as Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V. This structure supports the company's role as an investment holding vehicle rather than an operating biotech enterprise. By the period covered in the reference material, the board was chaired by Thomas von Planta, with Clive A. Meanwell serving as vice chairman. Christian Koch headed the investment management team from 2025. The portfolio included positions in companies such as Argenx, Ionis Pharmaceuticals, Neurocrine Biosciences, Intra-Cellular Therapies, Revolution Medicines, Vertex, Alnylam Pharmaceuticals, and Incyte. These holdings illustrate BB Biotech's continuing focus on drug developers and biotechnology platforms with potentially meaningful clinical or commercial catalysts.

• 2025

  Christian Koch leads investment management

  [1]BB Biotechen.wikipedia.org

  Christian Koch was identified as head of the investment management team.

• 2024

  Thomas von Planta chairs the board

  [1]BB Biotechen.wikipedia.org

  Thomas von Planta became chairman of the board of directors.

• 2023

  Italian trading ends

  [1]BB Biotechen.wikipedia.org

  BB Biotech shares ceased trading on the Italian Nuovo Mercato on September 4, 2023.

• 2015

  Second TecDAX period ends

  [1]BB Biotechen.wikipedia.org

  The company remained in the TecDAX until June 2015.

• 2012

  Return to the TecDAX

  [1]BB Biotechen.wikipedia.org

  BB Biotech returned to the TecDAX in September 2012 after leaving the index earlier that year.

• 2005

  Italian listing moves to the Star segment

  [1]BB Biotechen.wikipedia.org

  The Italian listing was included in the Star segment from September 2005.

• 2003

  First TecDAX period begins

  [1]BB Biotechen.wikipedia.org

  BB Biotech entered the TecDAX, remaining in the index until June 2012.

• 2000

  Italian market admission

  [1]BB Biotechen.wikipedia.org

  BB Biotech shares were admitted to Italy's Nuovo Mercato on October 19, 2000.

• 1997

  Frankfurt trading begins

  [1]BB Biotechen.wikipedia.org

  The shares began trading on Deutsche Börse in Frankfurt on December 10, 1997.

• 1993

  Company founded in Schaffhausen

  [1]BB Biotechen.wikipedia.org

  BB Biotech was established as a Swiss Aktiengesellschaft on November 9, 1993.

• 1993

  Initial SIX Swiss Exchange listing

  [1]BB Biotechen.wikipedia.org

  BB Biotech shares began trading on the SIX Swiss Exchange on December 27, 1993.

A listed, long-only biotechnology investment company offering investors professionally managed exposure to innovative drug developers and biotechnology platforms, with an emphasis on fundamental research and established or late-stage therapeutic opportunities.

• Listed investment security · 1993

  BB Biotech shares

  BB Biotech's principal investor-facing offering is its listed equity. The shares provide exposure to a professionally managed portfolio of biotechnology companies rather than to a single operating pharmaceutical business. Their exchange listing gives investors a tradable security through which to access a specialist biotechnology strategy.

• Specialist investment portfolio · 1993

  Biotechnology investment portfolio

  The portfolio is built through fundamental, bottom-up research and normally contains around 35 biotechnology holdings. It combines a concentrated group of core investments with smaller positions and may include a limited allocation to unlisted companies. Target areas include oncology, neurological, metabolic, cardiovascular, infectious, and autoimmune diseases, as well as cell, gene, and RNA-based therapies.

• 2023

  End of Italian market listingStrategy

  Background

  BB Biotech had traded in Italy since 2000 and in the Star segment since 2005.

  Action taken

  The shares ceased trading on the Italian Nuovo Mercato on September 4, 2023.

  Aftermath

  The company retained its Swiss and German market presence while ending its Italian listing.

  Source

• 1997

  Expansion of exchange access to GermanyStrategy

  Background

  After establishing a Swiss listing, BB Biotech sought broader access to European investors.

  Action taken

  The company's shares began trading on Deutsche Börse in Frankfurt.

  Aftermath

  The Frankfurt admission expanded the company's distribution across European capital markets.

  Source

• 1993

  Creation of a dedicated listed biotechnology investment vehicleStrategy

  Background

  BB Biotech was established to specialize in equity investments in biotechnology companies rather than to operate as a drug developer itself.

  Action taken

  The company adopted a closed-end investment-company structure and built its identity around specialist biotechnology exposure.

  Aftermath

  This structure remained central to BB Biotech's business model and capital-market positioning.

  Source

1. 1BB Biotechen.wikipedia.org